The immunogenetics of multiple sclerosis: A comprehensive review

Journal of Autoimmunity

Volumn 64, Issue , 2015, Pages 13-25

  Hollenbach, Jill A ^a   Oksenberg, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetics; Human leukocyte antigen; Killer cell immunoglobulin like receptor; Multiple sclerosis

Indexed keywords

AMINO ACID; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DRB1 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE ANTIGEN; HLA ANTIGEN;

ALLELE; AMINO ACID SUBSTITUTION; GENETIC ASSOCIATION; GENETIC RISK; HAPLOTYPE; HUMAN; IMMUNOGENETICS; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; IMMUNOLOGY;

ALLELES; ANIMALS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HLA ANTIGENS; HUMANS; IMMUNOGENETICS; MULTIPLE SCLEROSIS;

EID: 84946473364     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.06.010     Document Type: Review

References (171)

1. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
2. Hauser S.L., Goodin D.S. Multiple sclerosis and other demyelinating diseases. Harrison's Principle of Internal Medicine 2012, McGraw Hill, NY. 18th ed. D.L. Longo, A.D. Fauci, D.L. Kasper, S.L. Hauser, J.L. Jameson, J. Loscalzo (Eds.).
3. Lassmann H. Multiple sclerosis: lessons from molecular neuropathology. Exp. Neurol. 2014, 262(Pt A):2-7.
4. Simons M., Misgeld T., Kerschensteiner M. A unified cell biological perspective on axon-myelin injury. J. Cell. Biol. 2014, 206:335-345.
5. Hauser S.L. Multiple lessons for multiple sclerosis. N. Engl. J. Med. 2008, 359:1838-1841.
6. Hauser S.L., Chan J.R., Oksenberg J.R. Multiple sclerosis: prospects and promise. Ann. Neurol. 2013, 74:317-327.
7. Ontaneda D., Fox R.J., Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015, 14:208-223.
8. Pugliatti M., Sotgiu S., Rosati G. The worldwide prevalence of multiple sclerosis. Clin. Neurol. Neurosurg. 2002, 104:182-191.
9. Simpson S., Blizzard L., Otahal P., Van der Mei I., Taylor B. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J. Neurol. Neurosurg. Psychiatry 2011, 82:1132-1141.
10. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006, 5:932-936.
11. Koch-Henriksen N., Sorensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010, 9:520-532.
12. Wallin M.T., Page W.F., Kurtzke J.F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 2004, 55:65-71.
13. Wallin M.T., Culpepper W.J., Coffman P., Pulaski S., Maloni H., Mahan C.M., et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 2012, 135:1778-1785.
14. Langer-Gould A., Brara S.M., Beaber B.E., Zhang J.L. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology 2013, 80:1734-1739.
15. Cree B.A., Khan O., Bourdette D., Goodin D.S., Cohen J.A., Marrie R.A., et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004, 63:2039-2045.
16. Cree B.A., Reich D.E., Khan O., De Jager P.L., Nakashima I., Takahashi T., et al. Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch. Neurol. 2009, 66:226-233.
17. Sadovnick A.D., Baird P.A. The familial nature of multiple sclerosis: age-corrected empiric recurrence risks for children and siblings of patients. Neurology 1988, 38:990-991.
18. Robertson N.P., Fraser M., Deans J., Clayton D., Walker N., Compston D.A. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 1996, 119(Pt 2):449-455.
19. Willer C.J., Dyment D.A., Risch N.J., Sadovnick A.D., Ebers G.C. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12877-12882.
20. Ebers G.C., Sadovnick A.D., Risch N.J. A genetic basis for familial aggregation in multiple sclerosis. Nature 1995, 377:150-151.
21. Ebers G.C., Yee I.M., Sadovnick A.D., Duquette P. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann. Neurol. 2000, 48:927-931.
22. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007, 61:288-299.
23. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann. Neurol. 2007, 61:504-513.
24. Sawcer S., Franklin R.J., Ban M. Multiple sclerosis genetics. Lancet Neurol. 2014, 13:700-709.
25. Bertrams J., Kuwert E., Liedtke U. HLA antigens and multiple sclerosis. Tissue Antigens 1972, 2:405-408.
26. Maito S., Manerow N., Mickey M.R., Terasaki P.I. Multiple sclerosis: association with HL-A3. Tissue Antigens 1972, 2:1-4.
27. Vandiedonck C., Knight J.C. The human Major Histocompatibility Complex as a paradigm in genomics research. Brief. Funct. Genomic Proteomic 2009, 8:379-394.
28. Robinson J., Malik A., Parham P., Bodmer J.G., Marsh S.G. IMGT/HLA database-a sequence database for the human major histocompatibility complex. Tissue Antigens 2000, 55:280-287.
29. Cano P., Klitz W., Mack S.J., Maiers M., Marsh S.G., Noreen H., et al. Common and well-documented HLA alleles: report of the Ad-Hoc committee of the american society for histocompatiblity and immunogenetics. Hum. Immunol. 2007, 68:392-417.
30. Jersild C., Fog T., Hansen G.S., Thomsen M., Svejgaard A., Dupont B. Histocompatibility determinants in multiple sclerosis. Lancet 1973, ii:1221-1225.
31. Winchester R., Ebers G., Fu S.M., Espinosa L., Zabriskie J., Kunkel H.G. B-cell alloantigen Ag 7a in multiple sclerosis. Lancet 1975, 2:814.
32. Naito S., Namerow N., Mickey M.R., Terasaki P.I. Multiple sclerosis: association with HL-A3. Tissue antigens 1972, 2:1-4.
33. Compston D.A., Batchelor J.R., McDonald W.I. B-lymphocyte alloantigens associated with multiple sclerosis. Lancet 1976, 2:1261-1265.
34. Hauser S.L., Fleinschnick E., Weiner H.L., Marcus D., Awdeh Z., Yunis E.J., et al. Extended major histocompatibility complex haplotypes in patients with multiple sclerosis. Neurol 1989, 39:275-277.
35. Haines J.L., Terwedow H.A., Burgess K., Pericak-Vance M.A., Rimmler J.B., Martin E.R., et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum. Mol. Genet. 1998, 7:1229-1234.
36. Terasaki P.I. Selection of organ donors. N. Engl. J. Med. 1969, 280:1304.
37. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 2005, 5:201-214.
38. de Bakker P.I., Raychaudhuri S. Interrogating the major histocompatibility complex with high-throughput genomics. Hum. Mol. Genet. 2012, 21:R29-R36.
39. Olerup O., Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue antigens 1991, 38:1-15.
40. Barcellos L.F., Oksenberg J.R., Green A.J., Bucher P., Rimmler J.B., Schmidt S., et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002, 125:150-158.
41. Schmidt H., Williamson D., Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am. J. Epidemiol. 2007, 165:1097-1109.
42. Consortium TIMSGCtWTCC Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
43. Barcellos L.F., Oksenberg J.R., Begovich A.B., Martin E.R., Schmidt S., Vittinghoff E., et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 2003, 72:710-716.
44. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet. 2006, 15:2813-2824.
45. Vader W., Stepniak D., Kooy Y., Mearin L., Thompson A., van Rood J.J., et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12390-12395.
46. van der Heide A., Verduijn W., Haasnoot G.W., Drabbels J.J., Lammers G.J., Claas F.H. HLA dosage effect in narcolepsy with cataplexy. Immunogenetics 2015, 67:1-6.
47. Mackie S.L., Taylor J.C., Martin S.G., Wordsworth P., et al. A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. Genes. Immun. 2012, 13:120-128. Consortium Y, Consortium UConsortium U.
48. Noble J.A., Erlich H.A. Genetics of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2012, 2:a007732.
49. Dyment D.A., Herrera B.M., Cader M.Z., Willer C.J., Lincoln M.R., Sadovnick A.D., et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum. Mol. Genet. 2005, 14:2019-2026.
50. Kwon O.J., Karni A., Israel S., Brautbar C., Amar A., Meiner Z., et al. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Arch. Neurol. 1999, 56:555-560.
51. Hensiek A.E., Sawcer S.J., Feakes R., Deans J., Mander A., Akesson E., et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2002, 72:184-187.
52. Celius E.G., Harbo H.F., Egeland T., Vartdal F., Vandivik B., Spurkland A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J. Neurol. Sci. 2000, 178:132-135.
53. Okuda D.T., Srinivasan R., Oksenberg J.R., Goodin D.S., Baranzini S.E., Beheshtian A., et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009, 132:250-259.
54. Patsopoulos N.A., Barcellos L.F., Hintzen R.Q., Schaefer C., van Duijn C.M., Noble J.A., et al. Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects. PLoS Genet. 2013, 9:e1003926.
55. Marrosu M.G., Murru R., Murru M.R., Costa G., Zavattari P., Whalen M., et al. Dissection of the HLA association with multiple sclerosis in the founder isolated population of Sardinia. Hum. Mol. Genet. 2001, 10:2907-2916.
56. Thomson G., Valdes A.M., Noble J.A., Kockum I., Grote M.N., Najman J., et al. Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue antigens 2007, 70:110-127.
57. Nepom G.T., Hansen J.A., Nepom B.S. The molecular basis for HLA class II associations with rheumatoid arthritis. J. Clin. Immunol. 1987, 7:1-7.
58. Kooy-Winkelaar Y., van Lummel M., Moustakas A.K., Schweizer J., Mearin M.L., Mulder C.J., et al. Gluten-specific T cells cross-react between HLA-DQ8 and the HLA-DQ2alpha/DQ8beta transdimer. J. Immunol. 2011, 187:5123-5129.
59. Matsuki K., Grumet F.C., Lin X., Gelb M., Guilleminault C., Dement W.C., et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 1992, 339:1052.
60. Oksenberg J.R., Barcellos L.F., Cree B.A., Baranzini S.E., Bugawan T.L., Khan O., et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am. J. Hum. Genet. 2004, 74:160-167.
61. Quelvennec E., Bera O., Cabre P., Alizadeh M., Smadja D., Jugde F., et al. Genetic and functional studies in multiple sclerosis patients from Martinique attest for a specific and direct role of the HLA-DR locus in the syndrome. Tissue Antigens 2003, 61:166-171.
62. Lincoln M.R., Ramagopalan S.V., Chao M.J., Herrera B.M., Deluca G.C., Orton S.M., et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7542-7547.
63. Yoshimura S., Isobe N., Yonekawa T., Matsushita T., Masaki K., Sato S., et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One 2012, 7:e48592.
64. Matsuoka T., Matsushita T., Osoegawa M., Kawano Y., Minohara M., Mihara F., et al. Association of the HLA-DRB1 alleles with characteristic MRI features of Asian multiple sclerosis. Mult. Scler. 2008, 14:1181-1190.
65. Marrosu M.G., Muntoni F., Murru M.R. Sardinian multiple sclerosis is associated with HLA-DR4: A serological and molecular analysis. Neurology 1988, 38:1749-1753.
66. Brassat D., Salemi G., Barcellos L., McNeill G., Proia P., Hauser S.L., et al. The HLA locus and multiple sclerosis in Sicily. Neurology 2005, 64:361-363.
67. Isobe N., Gourraud P.A., Harbo H.F., Caillier S.J., Santaniello A., Khankhanian P., et al. Genetic risk variants in African Americans with multiple sclerosis. Neurology 2013, 81:219-227.
68. Modin H., Olsson W., Hillert J., Masterman T. Modes of action of HLA-DR susceptibility specificities in multiple sclerosis. Am. J. Hum. Genet. 2004, 74:1321-1322.
69. Marrosu M.G., Murru M.R., Costa G., Cucca F., Sotgiu S., Rosati G., et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. Am. J. Hum. Genet. 1997, 61:454-457.
70. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., Patsopoulos N.A., Moutsianas L., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
71. Karni A., Kohn Y., Safirman C., Abramsky O., Barcellos L., Oksenberg J.R., et al. Evidence for the genetic role of human leukocyte antigens in low frequency DRB1*1501 multiple sclerosis patients in Israel. Mult. Scler. 1999, 5:410-415.
72. Cocco E., Sardu C., Pieroni E., Valentini M., Murru R., Costa G., et al. HLA-DRB1-DQB1 haplotypes confer susceptibility and resistance to multiple sclerosis in Sardinia. PLoS One 2012, 7:e33972.
73. Amirzargar A., Mytilineos J., Yousefipour A., Farjadian S., Scherer S., Opelz G., et al. HLA class II associated genetic susceptibility in Iranian multiple sclerosis patients. Eur. J. Immunogenet 1998, 25:297-301.
74. Brum D.G., Barreira A.A., Louzada-Junior P., Mendes-Junior C.T., Donadi E.A. Association of the HLA-DRB1*15 allele group and the DRB1*1501 and DRB1*1503 alleles with multiple sclerosis in White and Mulatto samples from Brazil. J. Neuroimmunol. 2007, 189:118-124.
75. Sollid L.M., Pos W., Wucherpfennig K.W. Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Curr. Opin. Immunol. 2014, 31:24-30.
76. Hollenbach J.A., Thompson S.D., Bugawan T.L., Ryan M., Sudman M., Marion M., et al. Juvenile idiopathic arthritis and HLA class I and class II interactions and age-at-onset effects. Arthritis Rheum. 2010, 62:1781-1791.
77. Verreck F.A., Termijtelen A., Koning F. HLA-DR beta chain residue 86 controls DR alpha beta dimer stability. Eur. J. Immunol. 1993, 23:1346-1350.
78. Finn T.P., Jones R.E., Rich C., Dahan R., Link J., David C.S., et al. HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes. J. Neurosci. Res. 2004, 78:100-114.
79. Greenbaum J., Sidney J., Chung J., Brander C., Peters B., Sette A. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 2011, 63:325-335.
80. Lund O., Nielsen M., Kesmir C., Petersen A.G., Lundegaard C., Worning P., et al. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 2004, 55:797-810.
81. Caillier S.J., Briggs F., Cree B.A., Baranzini S.E., Fernandez-Vina M., Ramsay P.P., et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J. Immunol. 2008, 181:5473-5480.
82. Marsh S.G., Albert E.D., Bodmer W.F., Bontrop R.E., Dupont B., Erlich H.A., et al. Nomenclature for factors of the HLA system. Tissue Antigens 2010, 2010(75):291-455.
83. Gregersen J.W., Kranc K.R., Ke X., Svendsen P., Madsen L.S., Thomsen A.R., et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature 2006, 443:574-577.
84. Field J., Browning S.R., Johnson L.J., Danoy P., Varney M.D., Tait B.D., et al. A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis. PLoS One 2010, 5:e13454.
85. Dekker J.W., Easteal S., Jakobsen I.B., Gao X., Stewart G.J., Buhler M.M., et al. HLA-DPB1 alleles correlate with risk for multiple sclerosis in Caucasoid and Cantonese patients lacking the high-risk DQB1*0602 allele. Tissue Antigens 1993, 41:31-36.
86. Fukazawa T., Kikuchi S., Miyagishi R., Miyazaki Y., Yabe I., Hamada T., et al. HLA-dPB1*0501 is not uniquely associated with opticospinal multiple sclerosis in Japanese patients. Important role of DPB1*0301. Mult. Scler. 2006, 12:19-23.
87. Marrosu M.G., Cocco E., Costa G., Murru M.R., Mancosu C., Murru R., et al. Interaction of loci within the HLA region influences multiple sclerosis course in the Sardinian population. J. Neurol. 2006, 253:208-213.
88. Wu X.M., Wang C., Zhang K.N., Lin A.Y., Kira J., Hu G.Z., et al. Association of susceptibility to multiple sclerosis in Southern Han Chinese with HLA-DRB1, -DPB1 alleles and DRB1-DPB1 haplotypes: distinct from other populations. Mult. Scler. 2009, 15:1422-1430.
89. Matsushita T., Matsuoka T., Isobe N., Kawano Y., Minohara M., Shi N., et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 2009, 73:171-176.
90. Ramagopalan S.V., Anderson C., Sadovnick A.D., Ebers G.C. Genomewide study of multiple sclerosis. N. Engl. J. Med. 2007, 357:2199-2200. author reply 200-1.
91. Kaimen-Maciel D.R., Reiche E.M., Borelli S.D., Morimoto H.K., Melo F.C., Lopes J., et al. HLA-DRB1* allele-associated genetic susceptibility and protection against multiple sclerosis in Brazilian patients. Mol. Med. Reports 2009, 2:993-998.
92. Ramagopalan S.V., Morris A.P., Dyment D.A., Herrera B.M., DeLuca G.C., Lincoln M.R., et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet. 2007, 3:1607-1613.
93. Laaksonen M., Pastinen T., Sjoroos M., Kuokkanen S., Ruutiainen J., Sumelahti M.L., et al. HLA class II associated risk and protection against multiple sclerosis-a Finnish family study. J. Neuroimmunol. 2002, 122:140-145.
94. Tsai S., Santamaria P. MHC Class II Polymorphisms, Autoreactive T-Cells, and Autoimmunity. Front. Immunol. 2013, 4:321.
95. Harbo H.F., Lie B.A., Sawcer S., Celius E.G., Dai K.Z., Oturai A., et al. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 2004, 63:237-247.
96. Fogdell-Hahn A., Ligers A., Gronning M., Hillert J., Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000, 55:140-148.
97. Chao M.J., Barnardo M.C., Lui G.Z., Lincoln M.R., Ramagopalan S.V., Herrera B.M., et al. Transmission of class I/II multi-locus MHC haplotypes and multiple sclerosis susceptibility: accounting for linkage disequilibrium. Hum. Mol. Genet. 2007, 16:1951-1958.
98. Brynedal B., Duvefelt K., Jonasdottir G., Roos I.M., Akesson E., Palmgren J., et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2007, 2:e664.
99. Bergamaschi L., Leone M.A., Fasano M.E., Guerini F.R., Ferrante D., Bolognesi E., et al. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes. Immun. 2010, 11:173-180.
100. Harbo H.F., Isobe N., Berg-Hansen P., Bos S.D., Caillier S.J., Gustavsen M.W., et al. Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis. Mult. Scler. 2013, 6:660-668.
101. Rioux J.D., Goyette P., Vyse T.J., Hammarstrom L., Fernando M.M., Green T., et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18680-18685.
102. Yeo T.W., De Jager P.L., Gregory S.G., Barcellos L.F., Walton A., Goris A., et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann. Neurol. 2007, 61:228-236.
103. Wissemann W.T., Hill-Burns E.M., Zabetian C.P., Factor S.A., Patsopoulos N., Hoglund B., et al. Association of Parkinson disease with structural and regulatory variants in the HLA region. Am. J. Hum. Genet. 2013, 93:984-993.
104. Vlachopoulou E., Lahtela E., Wennerstrom A., Havulinna A.S., Salo P., Perola M., et al. Evaluation of HLA-DRB1 imputation using a Finnish dataset. Tissue antigens 2014, 83:350-355.
105. Hsieh A.R., Chang S.W., Chen P.L., Chu C.C., Hsiao C.L., Yang W.S., et al. Predicting HLA genotypes using unphased and flanking single-nucleotide polymorphisms in Han Chinese population. BMC Genomics 2014, 15:81.
106. Pillai N.E., Okada Y., Saw W.Y., Ong R.T., Wang X., Tantoso E., et al. Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations. Hum. Mol. Genet. 2014, 23:4443-4451.
107. Halperin E., Stephan D.A. SNP imputation in association studies. Nat. Biotechnol. 2009, 27:349-351.
108. Servin B., Stephens M. Imputation-based analysis of association studies: candidate regions and quantitative traits. PLoS Genet. 2007, 3:e114.
109. Dilthey A., Leslie S., Moutsianas L., Shen J., Cox C., Nelson M.R., et al. Multi-population classical HLA type imputation. PLoS Comput. Biol. 2013, 9:e1002877.
110. Zheng X., Shen J., Cox C., Wakefield J.C., Ehm M.G., Nelson M.R., et al. HIBAG-HLA genotype imputation with attribute bagging. Pharmacogen. J. 2014, 14:192-200.
111. Dilthey A.T., Moutsianas L., Leslie S., McVean G. HLA*IMP-an integrated framework for imputing classical HLA alleles from SNP genotypes. Bioinforma. Oxf. Engl. 2011, 27:968-972.
112. Erlich H.A., Gyllensten U.B. Shared epitopes among HLA class II alleles: gene conversion, common ancestry and balancing selection. Immunol. Today 1991, 12:411-414.
113. Karinen H., Karkkainen P., Pihlajamaki J., Janatuinen E., Heikkinen M., Julkunen R., et al. Gene dose effect of the DQB1*0201 allele contributes to severity of coeliac disease. Scand. J. Gastroenterol. 2006, 41:191-199.
114. Masterman T., Ligers A., Olsson T., Andersson M., Olerup O., Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann. Neurol. 2000, 48:211-219.
115. Deschamps R., Paturel L., Jeannin S., Chausson N., Olindo S., Bera O., et al. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. Mult. Scler. 2011, 17:24-31.
116. Gregersen P.K., Kosoy R., Lee A.T., Lamb J., Sussman J., McKee D., et al. Risk for myasthenia gravis maps to a (151) Pro-->Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann. Neurol. 2012, 72:927-935.
117. Emile J., Truelle J.L., Pouplard A., Hurez D. [Association of Parkinson's disease with HLA-B17 and B18 antigens]. Nouv. Presse Med. 1977, 6:4144.
118. Hamza T.H., Payami H. The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factors. J. Hum. Genet. 2010, 55:241-243.
119. Nalls M.A., Plagnol V., Hernandez D.G., Sharma M., Sheerin U.M., Saad M., et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011, 377:641-649.
120. Ahmed I., Tamouza R., Delord M., Krishnamoorthy R., Tzourio C., Mulot C., et al. Association between Parkinson's disease and the HLA-DRB1 locus. Mov. Disord. 2012, 27:1104-1110.
121. Nalls M.A., Pankratz N., Lill C.M., Do C.B., Hernandez D.G., Saad M., et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 2014, 46:989-993.
122. Eberhard G., Franzen G., Low B. Schizophrenia susceptibility and HL-A antigen. Neuropsychobiology 1975, 1:211-217.
123. Amar A., Zohar M., Tiwari J., Brautbar C. HLA and schizophrenia in Israel. Isr. J. Med. Sci. 1988, 24:28-31.
124. Stefansson H., Ophoff R.A., Steinberg S., Andreassen O.A., Cichon S., Rujescu D., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
125. Shi J., Levinson D.F., Duan J., Sanders A.R., Zheng Y., Pe'er I., et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
126. Jia P., Wang L., Fanous A.H., Pato C.N., Edwards T.L., Zhao Z. Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput. Biol. 2012, 8:e1002587.
127. Andreassen O.A., Harbo H.F., Wang Y., Thompson W.K., Schork A.J., Mattingsdal M., et al. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol. Psychiatry 2014, 20:207-214.
128. 2 ISGCatWTCCC Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biol. Psychiatry 2012, 72:620-628.
129. Andreassen O.A., Harbo H.F., Wang Y., Thompson W.K., Schork A.J., Mattingsdal M., et al. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol. Psychiatry 2015, 20:207-214.
130. van Bergen J., Kooy-Winkelaar E.M., van Dongen H., van Gaalen F.A., Thompson A., Huizinga T.W., et al. Functional killer Ig-like receptors on human memory CD4+ T cells specific for cytomegalovirus. J. Immunol. 2009, 182:4175-4182.
131. Hartung H.P., Aktas O., Menge T., Kieseier B.C. Immune regulation of multiple sclerosis. Handb. Clin. Neurol. 2014, 122:3-14.
132. Biron C.A. Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 1997, 9:24-34.
133. Bashirova A.A., Martin M.P., McVicar D.W., Carrington M. The Killer Immunoglobulin-like Receptor Gene Cluster: tuning the Genome for Defense. Annu Rev. Genomics Hum. Genet. 2006, 7:277-300.
134. Parham P., Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat. Rev. Immunol. 2013, 13:133-144.
135. Parham P. Influence of KIR diversity on human immunity. Adv. Exp. Med. Biol. 2005, 560:47-50.
136. Hollenbach J.A., Nocedal I., Ladner M.B., Single R.M., Trachtenberg E.A. Killer Cell Immunoglobulin-like Receptor (KIR) Gene-Content Variation in the HGDP-CEPH Populations. Immunogenetics 2012, 64:719-737.
137. Hollenbach J.A., Augusto D.G., Alaez C., Bubnova L., Fae I., Fischer G., et al. 16(th) IHIW: population Global Distribution of Killer Immunoglobulin-like Receptor (KIR) and Ligands. Int. J. Immunogenet. 2013, 40:39-45.
138. Colonna M., Moretta A., Vely F., Vivier E. A high-resolution view of NK-cell receptors: structure and function. Immunol. Today 2000, 21:428-431.
139. Moretta L., Bottino C., Pende D., Castriconi R., Mingari M.C., Moretta A. Surface NK receptors and their ligands on tumor cells. Semin. Immunol. 2006, 18:151-158.
140. Fadda L., Borhis G., Ahmed P., Cheent K., Pageon S.V., Cazaly A., et al. Peptide antagonism as a mechanism for NK cell activation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10160-10165.
141. Moesta A.K., Norman P.J., Yawata M., Yawata N., Gleimer M., Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J. Immunol. 2008, 180:3969-3979.
142. Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., et al. Cutting Edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 2007, 178:33-37.
143. Cassidy S.A., Cheent K.S., Khakoo S.I. Effects of Peptide on NK cell-mediated MHC I recognition. Front. Immunol. 2014, 5:133.
144. Cortes A., Brown M.A. Promise and pitfalls of the Immunochip. Arthritis Res. Ther. 2011, 13:101.
145. Kulkarni S., Martin M.P., Carrington M. The Yin and Yang of HLA and KIR in human disease. Seminars Immunol. 2008, 20:343-352.
146. Lorentzen A.R., Karlsen T.H., Olsson M., Smestad C., Mero I.L., Woldseth B., et al. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann. Neurol. 2009, 65:658-666.
147. Kaur G., Trowsdale J., Fugger L. Natural killer cells and their receptors in multiple sclerosis. Brain 2013, 136:2657-2676.
148. Pelak K., Need A.C., Fellay J., Shianna K.V., Feng S., Urban T.J., et al. Copy number variation of KIR genes influences HIV-1 control. PLoS Biol. 2011, 9:e1001208.
149. Gourraud P.A., Gagne K., Bignon J.D., Cambon-Thomsen A., Middleton D. Preliminary analysis of a KIR haplotype estimation algorithm: a simulation study. Tissue Antigens 2007, 69(Suppl. 1):96-100.
150. Norman P.J., Hollenbach J.A., Nemat-Gorgani N., Guethlein L.A., Hilton H.G., Pando M.J., Koram K.A., Riley E.M., Abi-Rached L., Parham P. Co-evolution of Human Leukocyte Antigen (HLA) class I ligands with Killer-cell Immunoglobulin-like Receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet. 2013, 9(10):e10039.
151. Jelcic I., Hsu K.C., Kakalacheva K., Breiden P., Dupont B., Uhrberg M., et al. Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Mult. Scler. 2012, 18:951-958.
152. Garcia-Leon J.A., Pinto-Medel M.J., Garcia-Trujillo L., Lopez-Gomez C., Oliver-Martos B., Prat-Arrojo I., et al. Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol. Immunol. 2011, 48:1896-1902.
153. Bettencourt A., Silva A.M., Carvalho C., Leal B., Santos E., Costa P.P., et al. The role of KIR2DS1 in multiple sclerosis-KIR in Portuguese MS patients. J. Neuroimmunol. 2014, 269:52-55.
154. Fusco C., Guerini F.R., Nocera G., Ventrella G., Caputo D., Valentino M.A., et al. KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. J. Neuroimmunol. 2010, 229:232-237.
155. Xu W., Fazekas G., Hara H., Tabira T. Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 163:24-30.
156. Huang D., Shi F.D., Jung S., Pien G.C., Wang J., Salazar-Mather T.P., et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006, 20:896-905.
157. Hao J., Liu R., Piao W., Zhou Q., Vollmer T.L., Campagnolo D.I., et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 2010, 207:1907-1921.
158. Shi F.D., Takeda K., Akira S., Sarvetnick N., Ljunggren H.G. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J. Immunol. 2000, 165:3099-3104.
159. Vollmer T.L., Liu R., Price M., Rhodes S., La Cava A., Shi F.D. Differential effects of IL-21 during initiation and progression of autoimmunity against Neuroantigen. J. Immunol. 2005, 174:2696-2701.
160. Takahashi K., Miyake S., Kondo T., Terao K., Hatakenaka M., Hashimoto S., et al. Natural killer type 2 bias in remission of multiple sclerosis. J. Clin. Invest 2001, 107:R23-R29.
161. Takahashi K., Aranami T., Endoh M., Miyake S., Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004, 127:1917-1927.
162. Backstrom E., Chambers B.J., Kristensson K., Ljunggren H.G. Direct NK cell-mediated lysis of syngenic dorsal root ganglia neurons in vitro. J. Immunol. 2000, 165:4895-4900.
163. Backstrom E., Chambers B.J., Ho E.L., Naidenko O.V., Mariotti R., Fremont D.H., et al. Natural killer cell-mediated lysis of dorsal root ganglia neurons via RAE1/NKG2D interactions. Eur. J. Immunol. 2003, 33:92-100.
164. Hauser S.L., Ault K.A., Levin M.J., Garovoy M.R., Weiner H.L. Natural killer cell activity in multiple sclerosis. J. Immunol. 1981, 127:1114-1117.
165. De Santis D., Dinauer D., Duke J., Erlich H.A., Holcomb C.L., Lind C., et al. 16(th) IHIW : review of HLA typing by NGS. Int. J. Immunogenet 2013, 40:72-76.
166. Dubois V., Tiercy J.M., Labonne M.P., Dormoy A., Gebuhrer L. A new HLA-B44 allele (B*44020102S) with a splicing mutation leading to a complete deletion of exon 5. Tissue Antigens 2004, 63:173-180.
167. Hoarau J.J., Cesari M., Caillens H., Cadet F., Pabion M. HLA DQA1 genes generate multiple transcripts by alternative splicing and polyadenylation of the 3' untranslated region. Tissue Antigens 2004, 63:58-71.
168. Kulkarni S., Savan R., Qi Y., Gao X., Yuki Y., Bass S.E., et al. Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011, 472:495-498.
169. Gentle N.L., Paximadis M., Puren A., Tiemessen C.T. Genetic variability in markers of HLA-C expression in two diverse South African populations. PLoS One 2013, 8:e67780.
170. Salter R.D., Benjamin R.J., Wesley P.K., Buxton S.E., Garrett T.P., Clayberger C., et al. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature 1990, 345:41-46.
171. Rajapaksa U.S., Li D., Peng Y.C., McMichael A.J., Dong T., Xu X.N. HLA-B may be more protective against HIV-1 than HLA-A because it resists negative regulatory factor (Nef) mediated down-regulation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:13353-13358.